Karen Judith Koutsourades, PT | |
215 Washington Avenue Ext, Albany, NY 12205-5534 | |
(518) 452-0914 | |
(518) 452-5953 |
Full Name | Karen Judith Koutsourades |
---|---|
Gender | Female |
Speciality | Physical Therapist |
Location | 215 Washington Avenue Ext, Albany, New York |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154310258 | NPI | - | NPPES |
02549686 | Medicaid | NY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | 019759 (New York) | Primary |
Provider Name | Samaritan Hospital Of Troy, New York |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1043267727 PECOS PAC ID: 6507770070 Enrollment ID: O20031118000782 |
News Archive
In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack.
The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.
Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
› Verified 3 days ago
Provider Name | Memorial Hospital, Albany N.y. |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1801837539 PECOS PAC ID: 1052203312 Enrollment ID: O20040330000224 |
News Archive
In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack.
The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.
Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
› Verified 3 days ago
Provider Name | St Peters Hospital Of The City Of Albany |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1518042357 PECOS PAC ID: 2668460072 Enrollment ID: O20040504001301 |
News Archive
In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack.
The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.
Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Karen Judith Koutsourades, PT 215 Washington Avenue Ext, Albany, NY 12205-5534 Ph: (518) 452-0914 | Karen Judith Koutsourades, PT 215 Washington Avenue Ext, Albany, NY 12205-5534 Ph: (518) 452-0914 |
News Archive
In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack.
The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.
Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
› Verified 3 days ago
Jordan Iris Bakowski, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 900 Watervliet Shaker Rd, Suite 102, Albany, NY 12205 Phone: 518-862-4900 | |
Yuan Kenneth Jin, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 121 Everett Rd Ste 200, Albany, NY 12205 Phone: 518-489-2524 Fax: 518-489-3167 | |
Penelope M Blasch, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 314 S Manning Blvd, Albany, NY 12208 Phone: 518-453-2273 | |
Heather M. Lacasse, MPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 121 Everett Rd Health Park, Albany, NY 12205 Phone: 518-489-2524 Fax: 518-489-3167 | |
Marianna Vaysman, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 281 Sand Creek Rd, Albany, NY 12205 Phone: 518-459-1292 Fax: 518-459-1296 | |
Kimberly Silvernail Keane, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 314 S Manning Blvd, Albany, NY 12208 Phone: 518-453-2273 | |
Dr. Janel Lena Carver, D.P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 80 Clinton Ave Apt 1, Albany, NY 12210 Phone: 914-299-9514 |